AFP15h
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
The Street Journal6h
Brand-new painkiller approved by US health agency
A new type of painkiller aimed at treating pain from an injury or surgery has been approved by the US Food and Drug Administration (FDA). The drug suzetrigine, also known by its brand name Journavx, ...
Hosted on MSN48m
FDA approves 1st new class of opioid-free painkillers in over 20 years
The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.
GEN23h
Scratching an Itch: A Double-Edge Sword That Sharpens Inflammation and Immune Defenses
Researchers studied genetically modified mice that lack NP2 itch-sensing neurons, to investigate the connection between itch, ...
technologynetworks22h
US Approves Non-Opioid Painkiller: What Is It, and How Does It Work?
The US Food and Drug Administration (FDA) announced its approval of a non-opioid treatment for moderate–severe acute chronic ...
Medscape22h
Insights Into the Pharmacological Targeting of the Trigeminocervical Complex in the Context of Treatments of Migraine
Migraine is one of the most severe and debilitating brain disorders. Most scientists accept that it involves activation and sensitization of the trigeminovascular system, which includes the ...